Abstract
Magnolol, phenolic bioactive phytomolecule, is a potential antihepatitis B viral agent. Current study is to mechanistically analyze the probable site of action for magnolol. Magnolol has been docked with EF3-CaM adenylyl cyclase (1PK0), deoxycytidine kinase (2NOA), human nucleoside diphosphate kinase (3FKB), human hepatitis B viral capsid (1QGT), hepatitis B X-interacting protein (3MSH) proteins using GRIP docking methodology, and compared with reference ligands like adefovir diphosphate (active metabolite of adefovir), lamivudine, tenofovir monophosphate (active metabolite of tenofovir) and tenofovir diphosphate (active metabolite of tenofovir). Results revealed its preferential interactability towards 2NOA i.e. deoxycytidine kinase, which raise up its chance to get metabolized into phosphorylated analogs, providing further impetus for discovery and clinical development of semi-synthetic analogs of magnolol. Out of all the virtually designed magnolol derivatives, Leadgrow_ML1449 have superior binding affinities towards all the test proteins except EF3-CaM adenylyl cyclase.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
